News | May 08, 2026
Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
NEJM study shows strong protection across strains
The formulation contains 0.075% Capsaicin, a clinically proven ingredient along with menthol, camphor and eucalyptus oil
The standout story remains Wegovy, particularly its new oral formulation
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
